Literature DB >> 15362364

Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations.

Mauricio P Oyarzo1, Pei Lin, Armand Glassman, Carlos E Bueso-Ramos, Rajyalakshmi Luthra, L Jeffrey Medeiros.   

Abstract

We report 12 cases of t(6;9)(p23;q34)-positive acute myeloid leukemia (AML), all classified using the criteria of the World Health Organization classification. There were 10 women and 2 men with a median age of 51 years (range, 20-76 years). Dysplasia was present in all cases (9 previously untreated), and basophilia was present in 6 (50%). Immunophenotypic studies showed that the blasts were positive for CD9, CD13, CD33, CD38, CD117, and HLA-DR in all cases assessed. CD34 was positive in 11 (92%) of 12, and terminal deoxynucleotidyl transferase was positive in 7 (64%) of 11 cases. The t(6;9) was the only cytogenetic abnormality detected in 7 cases (58%), and 5 cases had additional chromosomal abnormalities. Of 8 cases assessed, 7 (88%) had flt3 gene mutations. We conclude that t(6;9)-positive AML cases have distinctive morphologic features, an immunophenotype suggesting origin from an early hematopoietic progenitor cell, and a high frequency of flt3 gene mutations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362364     DOI: 10.1309/5DGB-59KQ-A527-PD47

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

1.  Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.

Authors:  Armen Kasyan; L Jeffrey Medeiros; Zhuang Zuo; Favio P Santos; Farhad Ravandi-Kashani; Roberto Miranda; Saroj Vadhan-Raj; Hartmut Koeppen; Carlos E Bueso-Ramos
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

Review 2.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

Review 3.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

4.  Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.

Authors:  Aref Al-Kali; Sergej Konoplev; Erpei Lin; Tapan Kadia; Stefan Faderl; Farhad Ravandi; Mohamad Ayoubi; Mark Brandt; Jorge E Cortes; Hagop Kantarjian; Gautam Borthakur
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Authors:  Julie Damgaard Sandahl; Eva A Coenen; Erik Forestier; Jochen Harbott; Bertil Johansson; Gitte Kerndrup; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Jean-Michel Cayuela; Lucy Chilton; Maarten Fornerod; Valérie de Haas; Christine J Harrison; Hiroto Inaba; Gertjan J L Kaspers; Der-Cherng Liang; Franco Locatelli; Riccardo Masetti; Christine Perot; Susana C Raimondi; Katarina Reinhardt; Daisuke Tomizawa; Nils von Neuhoff; Marco Zecca; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Henrik Hasle
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

Review 6.  Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.

Authors:  Hillary Prescott; Hagop Kantarjian; Jorge Cortes; Farhad Ravandi
Journal:  Expert Opin Emerg Drugs       Date:  2011-03-22       Impact factor: 4.191

7.  Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation.

Authors:  Weina Chen; Sergej Konoplev; L Jeffrey Medeiros; Hartmut Koeppen; Vasiliki Leventaki; Saroj Vadhan-Raj; Dan Jones; Hagop M Kantarjian; Brunangelo Falini; Carlos E Bueso-Ramos
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

8.  CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.

Authors:  Sergej Konoplev; Pei Lin; C Cameron Yin; E Lin; Graciela M Nogueras González; Hagop M Kantarjian; Michael Andreeff; L Jeffrey Medeiros; Marina Konopleva
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09-11

Review 9.  FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Leuk Lymphoma       Date:  2013-06-05

Review 10.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.